10-41, there is more to

"Amateur hour.

Sure hope Eversana helps this clown show figure out the path forward."

What exactly has Eversana achieved to date other than a big bill for over ~$10 Mil CAN, but hold on, there is more to come, as stated in the MD&A of March 31, 2022, headed "Going Concern" on page 3. It states the following:

"As at March 31, 2022, the Group is also party to a commercialization partnership where corresponding estimated (descretionary) pre-commercialization activities over the next twelve months total approximately between $10.4 million and $18.5 million." This would be over and above what the company needs for normal business operations for the balance of 2022.  

I see all of this as placing the cart before the horse. We have no product that is FDA approved to date that is ready for commercialization. It seems that money spent already for the Open-Label COVID-19  Trial that met its early conclusion subsequent to March 31, 2022, maybe considered money waisted. And now we wait to find out what comes of the meeting with the FDA concerning the Type C meeting to review the clinical trial protocol for the Phase 3 study of ABL in high-risk COVID-19 outpatients scheduled for August. And from our experience with management dates given seem to linger on and on at a time when there are little to no funds to get anything done....and BOM2 is almost forgotten. 

Send in the clowns ... Koo